Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Johannes Foersch"'
Autor:
Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H.-H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Júlio Núñez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nyström, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, EMPRISE EU, East Asia Study Group
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD).
Externí odkaz:
https://doaj.org/article/a2bb1c7f2f2448239e817140320a7e7e
Autor:
Thomas Danne, Jochen Seufert, Christian Wagner, Kerstin König, Dirk Raddatz, Rosmarie Weber-Lauffer, Diether Erath, Jost Hilgenberg, Carsten Spies, Maximilian Gabler, Johannes Foersch, Ludwin Ley
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020)
Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/s
Externí odkaz:
https://doaj.org/article/5f456ea4af564371a50893a1c20901f8
Autor:
Matthias Riedl, Thomas Wilke, Johannes Foersch, Stephan Martin, Sabrina Mueller, Maximilian Gabler, Jens Aberle, S Geier, Nils Picker
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 12:1225-1237
Background A substantial share of type 2 diabetes mellitus (T2DM) patients receive insulin. However, little is known about the real-world treatment patterns around insulin initiation. Methods This was a retrospective claims data analysis. T2DM patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b46e9b5377f6871f85dc873aa0ea1aa3
https://doi.org/10.2147/dmso.s214288
https://doi.org/10.2147/dmso.s214288
Autor:
Thomas Wilke, Johannes Foersch, Nils Picker, Maximilian Gabler, Matthias Riedl, Jens Aberle, S Geier, Stephan Martin
Publikováno v:
Diabetes research and clinical practice. 174
Background This study describes real-world treatment-related outcomes and healthcare costs of German type 2 diabetes mellitus (T2D) patients who initiated insulin therapy. Methods This retrospective analysis includes German claims data from 01/01/201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5069d92141d51b5c7b2810516d575b67
https://pubmed.ncbi.nlm.nih.gov/33737213
https://pubmed.ncbi.nlm.nih.gov/33737213
Autor:
Thomas Wilke, Nils Picker, Sabrina Mueller, Silke Geier, Johannes Foersch, Jens Aberle, Stephan Martin, Matthias Riedl, Maximilian Gabler
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
A substantial share of type 2 diabetes mellitus (T2DM) patients receive insulin. However, little is known about the real-world treatment patterns around insulin initiation.This was a retrospective claims data analysis. T2DM patients who initiated an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56efaa55ad68fac87b850a77778c58b8
https://www.dovepress.com/httpswwwdovepresscomcorrigendum-real-world-insulin-therapy--peer-reviewed-article-DMSO
https://www.dovepress.com/httpswwwdovepresscomcorrigendum-real-world-insulin-therapy--peer-reviewed-article-DMSO
Autor:
Johannes Foersch, Dirk Raddatz, Christian Wagner, Carsten Spies, Rosmarie Weber-Lauffer, Kerstin König, Sascha R. Tittel, Diether Erath, Jost Hilgenberg, Jochen Seufert, Ludwin Ley, Maximilian Gabler, Peter Bramlage, Thomas Danne
Publikováno v:
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020)
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020)
IntroductionEmpagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e18ab9f653526b7b3583cbc826bee5
https://doi.org/10.1136/bmjdrc-2020-001486
https://doi.org/10.1136/bmjdrc-2020-001486
Autor:
Jochen Seufert, Thomas Forst, Johannes Foersch, Martin Pfohl, Thorsten Siegmund, Stefan Pscherer, Anja Borck, Peter Bramlage
Publikováno v:
Diabetesmetabolic syndrome. 11(1)
Optimal treatment intensification strategies in patients with type-2 diabetes mellitus (T2DM) receiving basal insulin supported oral antidiabetic therapy (BOT) remain controversial. The objective of the present study was to compare outcomes of BOT-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811eb77830007a90167149ab414388b0
https://pubmed.ncbi.nlm.nih.gov/27578616
https://pubmed.ncbi.nlm.nih.gov/27578616
Publikováno v:
Diabetes Care
OBJECTIVE To determine whether daily intake of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] is safe and improves β-cell function in patients with recently diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS Safety was assessed in an open study of 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb67cad10600113c4644b650a40436e
https://pubmed.ncbi.nlm.nih.gov/20357369
https://pubmed.ncbi.nlm.nih.gov/20357369